A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
D001856:Bone Marrow Examination; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D007362:Intensive Care Units; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007958:Leukocyte Count; D008935:Mitoguazone / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D006146:Guanidines; D003561:Cytarabine; D013866:Thioguanine; D008935:Mitoguazone; D003630:Daunorubicin